Clostridium difficile infection is a significant cause of infectious diarrhoea 
and is associated with considerable morbidity and mortality.1,2 Management of 
Clostridium difficile infection often requires treatment with antibiotics 
(metronidazole, vancomycin or fidaxomicin) alongside supportive care to manage 
hydration, electrolytes and nutrition. However, the risk of recurrence is 
approximately 20%.2 Here, we review the evidence for bezlotoxumab (▼ Zinplava - 
Merck Sharp & Dohme Limited), a monoclonal antibody licensed for the prevention 
of recurrence of Clostridium difficile in adults who are at high risk of 
recurrence.